SPI Pharma, Inc., a fully owned subsidiary of Associated British Foods, and the Functional Additives Division of Asahi Kasei Chemicals have agreed to form an alliance in the field of pharmaceutical additives. Beginning in January 2016, each company will co-market the other's pharmaceutical additives in the respective markets of the US/Canada and Japan.
SPI Pharma's product portfolio consists of antacid actives, vaccine adjuvants, taste-masked actives, functional excipients and drug delivery systems. This agreement is exclusive to include Mannogem® Mannitol for swallow tablets as well as chewable tablets and lozenges; and Pharmaburst®, a co-processed drug delivery system for orally disintegrating tablets (ODTs).
The pharmaceutical additives business of Asahi Kasei Chemicals is led by Ceolus™, microcrystalline cellulose (MCC), and Celphere™ (MCC Beads). The Ceolus product lineup includes highly compactable grades which are suitable for various challenging tablet formulations, while Celphere is used in controlled release applications.
The business alliance announced today will leverage the complementary products and sales channels of the two companies for mutual benefit.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.